Katherine Ruffner

3.9k total citations · 2 hit papers
31 papers, 2.0k citations indexed

About

Katherine Ruffner is a scholar working on Hematology, Oncology and Epidemiology. According to data from OpenAlex, Katherine Ruffner has authored 31 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 9 papers in Oncology and 8 papers in Epidemiology. Recurrent topics in Katherine Ruffner's work include Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (8 papers) and Herpesvirus Infections and Treatments (6 papers). Katherine Ruffner is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (8 papers) and Herpesvirus Infections and Treatments (6 papers). Katherine Ruffner collaborates with scholars based in United States, Canada and Germany. Katherine Ruffner's co-authors include Donald M. Coen, Amy Malick, James M. Markert, Robert L. Martuza, Charles B. C. Hwang, Keith D. Wilner, John M. Maris, Julie Laliberté, Delphine Rolland and Ashish M. Ingle and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Katherine Ruffner

29 papers receiving 1.9k citations

Hit Papers

Experimental Therapy of Human Glioma by Means of a Geneti... 1991 2026 2002 2014 1991 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
    1991 795 citations Robert L. Martuza, Amy Malick et al. Science profile →
  2. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    2013 477 citations Yaël P. Mossé, Megan S. Lim et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine Ruffner United States 12 823 771 678 577 299 31 2.0k
Akira Hangaishi Japan 28 583 0.7× 497 0.6× 1.1k 1.6× 361 0.6× 98 0.3× 86 2.7k
Lloyd Hutchinson United States 26 634 0.8× 392 0.5× 725 1.1× 903 1.6× 48 0.2× 80 2.4k
Ludvik R. Donner United States 24 329 0.4× 358 0.5× 473 0.7× 248 0.4× 197 0.7× 93 1.6k
B. Balme France 28 1.2k 1.4× 213 0.3× 466 0.7× 1.2k 2.0× 92 0.3× 170 2.8k
R C Moen United States 13 699 0.8× 1.2k 1.6× 1.2k 1.8× 183 0.3× 76 0.3× 20 2.3k
Neil L. Berinstein Canada 29 1.1k 1.3× 247 0.3× 792 1.2× 175 0.3× 202 0.7× 104 2.9k
Sergey Yurasov United States 20 421 0.5× 330 0.4× 696 1.0× 312 0.5× 124 0.4× 38 4.0k
Anne I.J. Arens Netherlands 18 552 0.7× 466 0.6× 897 1.3× 85 0.1× 64 0.2× 49 1.6k
Geoffrey R. Kitchingman United States 21 427 0.5× 733 1.0× 772 1.1× 161 0.3× 125 0.4× 46 1.8k
Aya Jakobovits United States 20 705 0.9× 369 0.5× 1.4k 2.1× 120 0.2× 114 0.4× 36 2.6k

Countries citing papers authored by Katherine Ruffner

Since Specialization
Citations

This map shows the geographic impact of Katherine Ruffner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Ruffner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Ruffner more than expected).

Fields of papers citing papers by Katherine Ruffner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Ruffner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Ruffner. The network helps show where Katherine Ruffner may publish in the future.

Co-authorship network of co-authors of Katherine Ruffner

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Ruffner. A scholar is included among the top collaborators of Katherine Ruffner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Ruffner. Katherine Ruffner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lenz, Heinz‐Josef, Anup Kasi, Timothy Lewis Cannon, et al.. (2022). A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology. 40(4_suppl). 100–100. 7 indexed citations
2.
Zeidan, Amer M., Maya Ridinger, Peter J.P. Croucher, et al.. (2021). Predictive Biomarkers of Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Decitabine in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). Blood. 138(Supplement 1). 3431–3431. 1 indexed citations
3.
Chen, Amy, Ons Harrabi, Abraham Fong, et al.. (2020). ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies. Blood. 136(Supplement 1). 15–16. 3 indexed citations
4.
Mossé, Yaël P., Megan S. Lim, Stephan D. Voss, et al.. (2013). Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet Oncology. 14(6). 472–480. 477 indexed citations breakdown →
5.
Cortes, Jörge E., Tim H. Brümmendorf, H. Jean Khoury, et al.. (2012). Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.. Blood. 120(21). 2798–2798. 3 indexed citations
6.
Bence‐Bruckler, Isabelle, D. Blair Macdonald, Patrick J. Stiff, et al.. (2010). A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL). Blood. 116(21). 428–428. 6 indexed citations
7.
Jagasia, Madan, Wichai Chinratanalab, Heidi Chen, et al.. (2007). Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria. Biology of Blood and Marrow Transplantation. 13(10). 1207–1215. 89 indexed citations
8.
Engelhardt, Brian G., Stephen J. Brandt, Wichai Chinratanalab, et al.. (2007). High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes. Leukemia & lymphoma. 48(9). 1728–1735. 6 indexed citations
9.
Kassim, Adetola A., Madan Jagasia, Madhuri Vusirikala, et al.. (2006). Reduced intensity matched related (MRD) and matched unrelated (MUD) allogeneic stem cell transplantation (RIST) in adults with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A single center experience. Biology of Blood and Marrow Transplantation. 12(2). 41–41. 1 indexed citations
10.
Jagasia, Madan, John P. Greer, Adetola A. Kassim, et al.. (2005). Pegylated filgrastim after high-dose chemotherapy and autologous stem cell transplant. 3. 68–69. 1 indexed citations
11.
Jagasia, Madan, John P. Greer, David Morgan, et al.. (2005). Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplantation. 35(12). 1165–1169. 35 indexed citations
12.
Brown, Charlotte A., Shin Mineishi, Madan Jagasia, et al.. (2005). Predictive value for engraftment and survival of total nucleated cell dose (TNC) as compared to CD34+ cell dose after autologous and allogeneic bone marrow transplant (BMT) for hematologic malignancies. Journal of Clinical Oncology. 23(16_suppl). 6706–6706. 1 indexed citations
13.
Pagel, John M., Frederick R. Appelbaum, Janet F. Eary, et al.. (2005). 131I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 107(5). 2184–2191. 107 indexed citations
14.
15.
Singer, Jack W., Sergio Giralt, Mark Goodman, et al.. (2004). 166Ho-DOTMP Skeletal Targeted Radiotherapy with melphalan and autologous stem cell support for multiple myeloma. Journal of Clinical Oncology. 22(14_suppl). 6656–6656.
16.
Pagel, John M., Frederick R. Appelbaum, Janet F. Eary, et al.. (2004). 131I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.. Blood. 104(11). 813–813. 5 indexed citations
17.
Hwang, Charles B. C., Katherine Ruffner, & Donald M. Coen. (1992). A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. Journal of Virology. 66(3). 1774–1776. 109 indexed citations
18.
Martuza, R L, Amy Malick, James M. Markert, Katherine Ruffner, & Donald M. Coen. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. The Society for Neuroscience Abstracts. 17. 1469. 2 indexed citations
19.
Martuza, Robert L., Amy Malick, James M. Markert, Katherine Ruffner, & Donald M. Coen. (1991). Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant. Science. 252(5007). 854–856. 795 indexed citations breakdown →
20.
Marcy, A I, Charles B. C. Hwang, Katherine Ruffner, & Donald M. Coen. (1990). Engineered herpes simplex virus DNA polymerase point mutants: the most highly conserved region shared among alpha-like DNA polymerases is involved in substrate recognition. Journal of Virology. 64(12). 5883–5890. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akira Hangaishi Breakdown of academic impact, for papers by Lloyd Hutchinson Breakdown of academic impact, for papers by Ludvik R. Donner Breakdown of academic impact, for papers by B. Balme Breakdown of academic impact, for papers by R C Moen Breakdown of academic impact, for papers by Neil L. Berinstein Breakdown of academic impact, for papers by Sergey Yurasov Breakdown of academic impact, for papers by Anne I.J. Arens Breakdown of academic impact, for papers by Geoffrey R. Kitchingman Breakdown of academic impact, for papers by Aya Jakobovits
Rankless by CCL
2026